Long-term outcome of patients given transplants of mobilized blood or bone marrow: A report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation.
We previously compared outcomes after allogeneic peripheral-blood stem cell (PBSC) and bone marrow (BM) transplantation in 706 patients with leukemia. We obtained long-term follow up on 413 of 491 patients who were alive at the time of the initial report: 141 PBSC and 272 BM recipients. Chronic graft-versus-host disease (GVHD) was more frequent after PBSC compared to BM transplantation (RR 1.65, P < .001) yet relapse rates were similar in both groups. Leukemia-free survival rates were higher after PBSC than BM transplantation for patients with advanced chronic myeloid leukemia (33% versus 25%) but lower for those in first chronic phase (41% versus 61%) due to higher rates of late transplant-related mortality. Leukemia-free survival was similar after PBSC and BM transplantation for acute leukemia. These data represent the early experience with PBSC grafts. Long-term outcomes in recipients of more recent transplants are required to better evaluate the role of PBSC grafts relative to BM transplantation.
Schmitz
Norbert
N
Department of Hematology, Asklepios Klinik St Georg, Hamburg, Germany.
Eapen
Mary
M
Horowitz
Mary M
MM
Zhang
Mei-Jie
MJ
Klein
John P
JP
Rizzo
J Douglas
JD
Loberiza
Fausto R
FR
Gratwohl
Alois
A
Champlin
Richard E
RE
D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000401:mortality; D002908:Chronic Disease; D018572:Disease-Free Survival; D005060:Europe; D005260:Female; D005500:Follow-Up Studies; D006086:Graft vs Host Disease / Q000209:etiology / Q000401:mortality*; D006801:Humans; D007938:Leukemia / Q000150:complications / Q000401:mortality* / Q000628:therapy; D008297:Male; D036102:Peripheral Blood Stem Cell Transplantation / Q000009:adverse effects / Q000401:mortality; D012042:Registries; D012189:Retrospective Studies; D015996:Survival Rate; D014184:Transplantation, Homologous